Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: A preliminary open-label study

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1360-1369

  Zhang, Qing ^a   Chen, Hong ^a   Li, Qin ^c   Zang, Yunjin ^a   Chen, Xinguo ^a   Zou, Weilong ^a   Wang, Letian ^a   Shen, Zhong Yang ^a,b  

^a GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

^c Shaanxi Carcinoma Hospital   (China)

Author keywords

Adjuvant chemotherapy; Hepatocellular carcinoma; Liver transplantation; Recurrence; Survival

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OPEN STUDY; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FOLLOW UP; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856070098     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9726-1     Document Type: Article

References (45)

1. Bosch FX, Ribes J, Borras J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19:271-285 (Pubitemid 29488770)
2. Poon RTP, Fan ST, Wong J (2000) Risk factors prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10-24 (Pubitemid 30456545)
3. Coelho GR, Vasconcelos KF, Vasconcelos JB et al (2009) Orthotopic liver transplantation for hepatocellular carcinoma: one center's experience in the Northeast of Brazil. Transplant Proc 41:1740-1742
4. Hertl M, Cosimi AB (2005) Liver transplantation for malignancy. Oncologist 10:269-281 (Pubitemid 40559592)
5. Varona MA, Del Pino JM, Barrera M et al (2009) Hepatocellular carcinoma and liver transplantation: a 12-year experience. Transplant Proc 41:1005-1008
6. Chen GH (2009) Liver transplantation in China: retrospect and prospect. Chin Med J 122:2229-2230
7. Fernandez JA, Robles R, Marin C et al (2003) Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 35:1818-1820 (Pubitemid 37093723)
8. Chu F, Morris DL (2006) Single centre experience of liver resection for hepatocellular carcinoma in patients outside transplant criteria. Eur J Surg Oncol 32:568-572
9. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699 (Pubitemid 26079803)
10. Yao FY, Ferrell L, Bass NM et al (2002) Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 8:765-774 (Pubitemid 35012284)
11. Gondolesi GE, Roayaie S, Muñoz L et al (2004) Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 239:142-149 (Pubitemid 38176346)
12. Coriat R, Mir O, Cessot A et al (2010) Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs Aug. 27 [Epub ahead of print]
13. Shimoda M, Ghobrial RM, Carmody IC et al (2004) Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl 10:1478-1486 (Pubitemid 40028380)
14. Marsh JW, Dvorchik I, Subotin M et al (1997) The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 26:444-450 (Pubitemid 27328324)
15. Gondolesi GE, Roayaie S, Muñoz L et al (2006) Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc 38:2495-2498
16. Kwok PC, Lam TW, Lam PW et al (2003) Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma. J Gastroenterol Hepatol 18:450-455 (Pubitemid 36549557)
17. Ono T, Yamanoi A, El N et al (2001) Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 91:2378-2385 (Pubitemid 32552825)
18. Hsieh CB, Chou SJ, Shih ML et al (2008) Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 34:906-910
19. Xia Y, Qiu Y, Li J et al (2010) Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol 17:3137-3144
20. Xu J, Zhong Y, Weixin N et al (2007) Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg 245:583-590 (Pubitemid 46555662)
21. Ragnhammar P, Hafström L, Nygren P et al (2001) Swedish council of technology assessment in health care. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40:282-308 (Pubitemid 32588124)
22. Trojan J, Lubomierski N, Lehnert T et al (2008) Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. Z Gastroenterol 46:776-779
23. Poggi G, Quaretti P, Minoia C et al (2008) Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEMTACE) for unresectable hepatic tumors. Anticancer Res 28:3835-3842
24. Uhm JE, Park JO, Lee J et al (2009) A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic vchemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 63:929-935
25. Li S, Niu Z, Tian H et al (2007) Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology 54:218-223 (Pubitemid 46511679)
26. Van Cutsem E, Van de Velde C, Roth A et al (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44:182-194
27. Wang GQ, Wan DS, Zhou ZW et al (2007) Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis. Ai Zheng 26:411-414
28. Raimondo ML, Burroughs AK (2002) Single-agent immunosuppression after liver transplantation: what is possible? Drugs 62:1587-1597 (Pubitemid 34848367)
29. Tobinai K, Kohno A, Shimada Y et al (1993) Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23:250-257
30. Yang BS, Ma YJ, Wang Y et al (2007) Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure. World J Gastroenterol 133:462-466 (Pubitemid 46178985)
31. Alp MH, Hickman R (1987) The effect of prostaglandins, branched-chain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure. J Hepatol 4:99-107 (Pubitemid 17045551)
32. Sutcliffe R, Maguire D, Murphy P et al (2005) Detection and clinical significance of bone marrow micrometastases in patients undergoing liver transplantation for hepatocellular carcinoma. Transplantation 80:88-94 (Pubitemid 40980900)
33. Olthoff KM, Rosove MH, Shackleton CR et al (1995) Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 221:734-743
34. Huang J, He X, Chen G et al (2002) Liver transplantation at the Sun Yat-Sen University of Medical Sciences in China. Chin Med J 115:543-548 (Pubitemid 34538098)
35. Roayaie S, Frischer JS, Emre SH et al (2002) Long term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinoma larger than 5 centimeters. Ann Surg 235:533-539 (Pubitemid 34258353)
36. Qin S, Bai Y, Ye S et al (2010) Thongprasert, Y. Chao, K, Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients, Journal of Clinical Oncology. 2010 ASCO Annual Meeting Proceedings. 28 suppl (May 20 Supplement) 4008
37. Cheng A-L, Kang Y-K, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
38. Lee JO, Kim DY, Lim JH et al (2009) Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 24:800-805
39. Vexler AM, Mou X, Gabizon AA et al (1995) Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. Int J Cancer 60:611-615
40. Boucher E, Corbinais S, Brissot P et al (2002) Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 50:305-308
41. Al-Batran SE, Atmaca A, Hegewisch-Becker S et al (2004) Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22:658-663 (Pubitemid 41102130)
42. Louvet C, André T, Tigaud JM et al (2002) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543-4548 (Pubitemid 35407422)
43. Gerard JP, Chapet O, Nemoz C et al (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 21:1119-1124 (Pubitemid 46594142)
44. Pettengell R, Aapro M, Brusamolino E et al (2009) Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. Clin Drug Investig 29:491-513
45. Liongue C, Wright C, Russell AP et al (2009) Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. Int J Biochem Cell Biol 41:2372-2375